GlobeNewsWire
12 Jan 2026, 13:47 UTC · 36w ago
Verdict
Headline takes no side. We score ACHV +0.40 across three claims — moderately bullish.
+0.40moderately bullish
More positive than 63% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has assigned a PDUFA date of June 20, 2026, for the review of cytisinicline for smoking cessation.
More positive than 92% of claims this week
Achieve Life Sciences has completed a Phase 2 study for vaping cessation and held a successful end-of-Phase 2 meeting with the FDA.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Mark Rubinstein, M.D., has been promoted from Interim to permanent Chief Medical Officer.
More positive than 41% of claims this week
Which stocks this story touches
More positive than 63% of ticker scores this week
The company confirmed a key leadership appointment and highlighted positive clinical milestones and an upcoming FDA PDUFA date.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
7h ago
+40.2%
Price agrees with the score
$7.80 vs $5.56 close before publication (Jan 9) · not market-adjusted
ACHV chart →
